SCHEMBL670110

SCHEMBL670110

O=[N+]([O-])c1ccc(N2CCNCC2)nc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.74
ALDH1A1 P00352 4/20 0.72
LMNA P02545 1/20 0.72
ALOX12 P18054 1/20 0.72
NPSR1 Q6W5P4 1/20 0.72
CYP1A2 P05177 2/20 0.68
CYP2C9 P11712 1/20 0.68
HPGD P15428 1/20 0.68
MEN1 O00255 4/20 0.65
KMT2A Q03164 4/20 0.65
ATM Q13315 1/20 0.65
HTR3E A5X5Y0 1/20 0.60
HTR3B O95264 1/20 0.60
CYP3A4 P08684 1/20 0.60
SLC6A4 P31645 1/20 0.60
CYP2C19 P33261 1/20 0.60
THPO P40225 1/20 0.60
HTR3A P46098 1/20 0.60
HTR3D Q70Z44 1/20 0.60
HTR3C Q8WXA8 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2254485 0.98 MAPT (0.72) MAPTALDH1A1LMNAALOX12NPSR1
Hydrochloric Acid SCHEMBL27757811 0.98 MAPT (0.72) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL2003294 0.94 MAPT (0.76) MAPTALDH1A1LMNAALOX12NPSR1
Trifluoroacetic Acid SCHEMBL1724842 0.88 MAPT (0.59) MAPTALDH1A1LMNAALOX12NPSR1
Tert-Butyl Formate SCHEMBL27729961 0.86 MAPT (0.56) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL28901609 0.86 MAPT (0.67) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL940256 0.85 MAPT (0.93) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL238818 0.85 MAPT (1.00) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL29739445 0.85 MAPT (0.93) MAPTALDH1A1LMNAALOX12NPSR1
SCHEMBL23612280 0.84 MAPT (0.55) MAPTALDH1A1LMNAALOX12NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 165 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140273458-A1 Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-18 US claimed
EP-2779217-A2 Chemical mechanical planarization for tungsten-containing substrates AIR PRODUCTS AND CHEMICALS, INC. (US) 2014-09-17 EP claimed
CN-104046246-A Chemical Mechanical Planarization for Tungsten-Containing Substrates AIR PROD & CHEM 2014-09-17 CN claimed
CN-1594298-A Pyridine ring containing oxazolidinone compounds and preparation process and application thereof SHANGHAI INST MATERIA MEDICA (CN) 2005-03-16 CN claimed
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY MAGICBULLETTHERAPEUTICS CO., LTD. (KR) 2025-05-01 US disclosed
EP-4442691-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY Magicbullettherapeutics Co., Ltd. (KR) 2024-10-09 EP disclosed
CN-118613486-A 2, 7-Substituted pyrrolo [2,1-F ] [1,2,4] triazine compounds having protein kinase inhibitory activity 魔法弹丸治疗 2024-09-06 CN disclosed
WO-2024173646-A1 CYCLIN-DEPENDENT KINASE DEGRADING COMPOUNDS INNOVO THERAPEUTICS, INC. (US) 2024-08-22 WO disclosed
WO-2023140629-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY 닥터아이앤비(주) 2023-07-27 WO disclosed
WO-2023101387-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY 연세대학교 산학협력단 2023-06-08 WO disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY NOVARTIS PHARMA AG (CH) 2023-04-27 US disclosed
EP-0770073-A1 ANTI-HELICOBACTER HETEROCYCLIC DERIVATIVES OF AZOLONES JANSSEN PHARMACEUTICA N.V. (BE) 1997-05-02 EP disclosed
US-5607932-A Heterocyclic derivatives of azolones JANSSEN PHARMACEUTICA N.V. (BE) 1997-03-04 US disclosed
WO-1996001821-A1 ANTI-HELICOBACTER HETEROCYCLIC DERIVATIVES OF AZOLONES JANSSEN PHARMACEUTICA N.V. (BE) 1996-01-25 WO disclosed
US-5120843-A Nervous system disorders UPJOHN (US) 1992-06-09 US disclosed
EP-0487510-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1992-05-27 EP disclosed
EP-0358676-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1990-03-21 EP disclosed
EP-0293078-A1 Pharmaceutically active amines THE UPJOHN COMPANY (US) 1988-11-30 EP disclosed
WO-1988008424-A1 PHARMACEUTICALLY ACTIVE AMINES THE UPJOHN COMPANY (US) 1988-11-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136614-A1 2,7-SUBSTITUTED PYRROLO[2,1-F][1,2,4]TRIAZINE COMPOUND HAVING PROTEIN KINASE INHIBITORY ACTIVITY STK25, MAP3K15, MAP3K5 MAPT 2860/4885ALDH1A1 3740/4885LMNA 4018/4885
US-20230127839-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY STING1, CGAS, IRF3 MAPT 3027/4885ALDH1A1 4654/4885LMNA 2339/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.